Exparel 266 MG/20 ML vial 20ML
Ended Awarded
- Contract number
- SPE2DB26FKDXV
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,043
Award facts
- Contract value 100% obligated
- $10,042.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $10,042.52 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, on October 30, 2025. The delivery order is for EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials, a specialty surgical anesthetic product, with an ultimate completion date of November 21, 2025. No set-aside designation was used for this award. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply pharmaceutical products to Department of Defense military healthcare facilities worldwide.
The PPV-G GEN V contract, designated SPE2DR and awarded to DMS Pharmaceutical Group on November 13, 2025, carries a ceiling value of $499,999,999 with a completion date of December 31, 2036. This IDC authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. DMS Pharmaceutical Group's established performance on numerous delivery orders across diverse therapeutic categories, ranging from oncology treatments to vaccines and emergency medications, demonstrates its capability as a critical pharmaceutical supplier supporting Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB26FKDXV?
SPE2DB26FKDXV was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 30, 2025.
How much is contract SPE2DB26FKDXV worth?
The government has obligated $10,043 on SPE2DB26FKDXV.
Is contract SPE2DB26FKDXV an order under another contract?
Yes. SPE2DB26FKDXV is a delivery order under SPE2DB24D9223, an indefinite delivery contract.
Was contract SPE2DB26FKDXV competed?
The extent of competition for SPE2DB26FKDXV was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award